Microglia & Neural Stem Cell Differentiation
The true potential of iPSCs and ESCs rest in its directed differentiation to different somatic lineages. As part of our comprehensive stem cell service platform, researchers can leverage our expertise in stem cell technologies and our cost-effective, reliable Stem Cell Differentiation Services for their developmental biology, disease mechanisms, and drug discovery research.
- Differentiate your patient-derived iPSCs into microglia and self-renewing, multipotent neural stem cells (NSCs) and further to neurons and glial cells.
- High differentiation efficiency and cell purity
- Cells fully characterized for microglia and NSC biomarkers
|Catalog ID#||Product Name||Price|
iPSC Differentiation into Neural Stem Cells (NSC)
Figure 1. iPSC-derived neural stem cells (NSC) expressing key NSC markers PAX6 and SOX 1 (green) cultured in feeder-free condition, differentiated using Applied StemCell's proprietary neural induction protocol. DAPI: nucleus staining (blue); White arrows: neuronal rosettes.
Figure 2. Differentiated NSCs retain neural stem cell phenotype even after free-thaw and passage under feeder-free condtions.
Induced Pluripotent Stem Cells (iPSCs) are exceedingly popular, like embryonic stem cells (ESCs), because their pluripotency allows them to differentiate into all three germ layers with the potential to differentiate into all cell types within the body, but unlike ESCs, they are not encumbered with the ethical dispute associated with the sourcing of ESCs. The true potential of stem cell technology lies in the directed terminal differentiation of iPSCs into specific somatic cells.
The process of iPSC differentiation to neurons and neuronal cells is of special importance for neurobiology and related disorders, considering the dearth of clinically relevant in vitro models available for research, drug screening and development, as well as the lack of therapy to reverse neuronal damage.
Benefits and advantages of iPSC differentiation to neural stem cells (NSC), neurons and glial cells:
- Provides genetic and physiologically relevant in vitro models to study neural development and associated disorders: congenital disorders, neurodegenerative disorders and brain tumors.
- Generate a valuable model for identifying new targets for neuro-regeneration as opposed to treatments limiting to symptomatic relief or delaying disease progression.
- Allows for future adaptation of technology for regenerative medicine and cell therapy in humans for the treatment of Parkinson’s disease, Lou-Gehrig disease (ALS), Huntington’s disease, and spinal cord injury among other diseases.
- Differentiation of genome engineered in iPSCs (mutation introduction or correction) to neurons, offers an isogenic source of control-disease cell lines for basic research, drug development, hard-to-model neurological disorders, and potentially for gene therapy.